AVENGER -Advanced LNP RNA Vaccines Engineered with Next-Generation designs to Enhance pandemic Readiness

• Lipid nanoparticle (LNP) messenger RNA technology is a leading approach for development of potent, well tolerated vaccines. AVENGER aims to be Canada’s LNP RNA vaccine platform by developing a library of optimized LNP formulations designed to generate long-lasting immunity to bacteria, which have very different immune requirements.

The project outcomes/aims include:

• Performing sequencing, reverse vaccinology, and antigen structure determination of S. aureus blood culture isolates
• Correlating sequences and antigen variants of S. aureus with clinical outcomes including hospital mortality; need for ventilation, vasopressors or renal replacement therapy; hospital admission and discharge dates for length of stay; need for and dates of ICU admission; S. aureus antibiotic resistance results